SCHEMBL4019099

SCHEMBL4019099

Cc1cccc([C@@H]2[C@@H](C(=O)c3cccc(F)c3)CN(CCN3CCOCC3)C[C@@H]2c2[c]cccc2F)c1C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.35
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
TP53 P04637 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
TDP2 O95551 1/20 0.34
CASP6 P55212 1/20 0.34
UBE2I P63279 1/20 0.34
HKDC1 Q2TB90 1/20 0.34
SAE1 Q9UBE0 1/20 0.34
UBA2 Q9UBT2 1/20 0.34
KDM4E B2RXH2 2/20 0.34
GAA P10253 2/20 0.34
GLA P06280 1/20 0.34
HPGD P15428 1/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4023939 0.98 MCHR1 (0.37) ALDH1A1NPC1RAB9ATP53SMN1; SMN2
SCHEMBL4020281 0.91 EED (0.34) ALDH1A1MEN1KMT2AGAAMCHR1
SCHEMBL4779404 0.91 MCHR1 (0.34) ALDH1A1MEN1KMT2AGAAMCHR1
SCHEMBL4779421 0.91 MCHR1 (0.34) ALDH1A1MEN1KMT2AGAAMCHR1
SCHEMBL4021786 0.87 ALDH1A1 (0.42) ALDH1A1NPC1RAB9ATP53SMN1; SMN2
SCHEMBL4019805 0.84 ALDH1A1 (0.41) ALDH1A1NPC1RAB9ATP53SMN1; SMN2
SCHEMBL4025011 0.83 MCHR1 (0.30) MCHR1
SCHEMBL4028159 0.77 ALDH1A1 (0.39) ALDH1A1MEN1KMT2AGAAMCHR1
SCHEMBL4779411 0.77 MC4R (0.34) ALDH1A1MEN1KMT2AGAAMCHR1
SCHEMBL4780063 0.77 ALDH1A1 (0.46) ALDH1A1RAB9ASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US disclosed
EP-1962846-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-09-03 EP disclosed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US disclosed
WO-2007059323-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161674-A1 Certain chemical entities, compositions, and methods TP53, VHL, RB1 ALDH1A1 258/4885NPC1 263/4885RAB9A 2228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.